Get the Stockscreener App
1.90
7.34%
0.13
Tvardi Therapeutics Inc stock is traded at $1.90, with a volume of 345.66K.
It is up +7.34% in the last 24 hours and down -38.71% over the past month.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
See More
Previous Close:
$1.77
Open:
$1.81
24h Volume:
345.66K
Relative Volume:
0.16
Market Cap:
$23.74M
Revenue:
$2.14M
Net Income/Loss:
$-15.44M
P/E Ratio:
-0.614
EPS:
-3.0946
Net Cash Flow:
$-24.67M
1W Performance:
+1.60%
1M Performance:
-38.71%
6M Performance:
-48.92%
1Y Performance:
-92.01%
1-Day Range:
$1.81
$2.04
1-Week Range:
$1.70
$2.04
52-Week Range:
$1.50
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Name
Tvardi Therapeutics Inc
Sector
Industry
Phone
(713) 489-8654
Address
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
1.90 | 22.11M | 2.14M | -15.44M | -24.67M | -3.0946 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-14-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-14-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Oct-13-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-13-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-14-25 | Initiated | Raymond James | Outperform |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | Piper Sandler | Overweight |
| May-21-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Initiated | BTIG Research | Buy |
| Jun-13-24 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-13-24 | Downgrade | Needham | Buy → Hold |
| Jun-13-24 | Downgrade | Stifel | Buy → Hold |
| Mar-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-08-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-01-21 | Resumed | Canaccord Genuity | Buy |
| Aug-03-21 | Initiated | JP Morgan | Neutral |
| Apr-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-19 | Reiterated | H.C. Wainwright | Buy |
| May-29-19 | Reiterated | Laidlaw | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Jan-15-19 | Initiated | BofA/Merrill | Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Jefferies | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jun-28-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-12-18 | Resumed | H.C. Wainwright | Buy |
| Feb-12-18 | Upgrade | Janney | Neutral → Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
View All
Tvardi Therapeutics Inc Stock (TVRD) Latest News
Tvardi Reports $6.5 Million Second-Quarter Net Loss and TTI-109 UC Plans - Moomoo
Tvardi Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Tvardi Q2 net loss reaches $6.5 million - grafa.com
Tvardi Therapeutics Reports Q2 2026 Net Loss of $6.5 Million - Minichart
Tvardi Q2 EPS $(0.69) beats $(0.70) estimate, loss narrows 31% - scanx.trade
Form 8K Tvardi Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Tvardi Therapeutics, Inc. 2026: Revenue ($6.46M), EPS ($0.69) — 10-Q Summary - TradingView
Tvardi Reports Positive TTI-109 Data, Picks Ulcerative Colitis for Next-Gen Drug - Minichart
Tvardi Therapeutics: Q2 2026 saw a $6.5M net loss, cash of $15.8M, and urgent need for additional funding - TradingView
Tvardi posts Q2 2026 net loss of $6.5M, cash $15.8M; reports TTI-109 healthy volunteer topline - TradingView
Tvardi Therapeutics: TTI-109 advanced for UC after positive topline results; Q2 net loss was $6.5 million - TradingView
Tvardi: Q2 Earnings Snapshot - 10TV
BRIEF-Tvardi Therapeutics Inc Q2 Net Income USD -6.5 Million Vs. IBES Estimate USD -6.54 Million - TradingView
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update - GlobeNewswire
Tvardi Therapeutics to Host KOL Webinar on the Clinical - GlobeNewswire
JonesTrading Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Tvardi Therapeutics, Inc. Revenue Breakdown – NASDAQ:TVRD - TradingView
Tvardi Therapeutics, Inc. expected to post a loss of 70 cents a shareEarnings Preview - TradingView
Tvardi Therapeutics Ord Shs (TVRD) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Enterprise value to revenue forward of Tvardi Therapeutics Inc. – FWB:69C - TradingView
TVRD Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109, Plans 2027 Clinical Trial - quiverquant.com
Tvardi's TTI-109 Shows Up to 76% Immune-Cell Reduction in Phase 1 - Stock Titan
Tvardi Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Pipeline ProgressEarnings Manipulation Risk - dars.gov.et
TVRD|Tvardi Therapeutics Ord Shs|Price:2.555|Chg%:+0.045 - TradingKey
Tvardi Therapeutics Ord Shs (TVRD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tvardi Therapeutics Ord Shs (TVRD) Institutional Confidence - TradingKey
Tvardi Therapeutics (TVRD) Edges Higher, Testing Key Resistance LevelsCounter Trend Trade - dars.gov.et
Tvardi Therapeutics Inc. Revenue Breakdown – LS:A414VY - TradingView
Tvardi Therapeutics Inc. Revenue Breakdown – LSX:A414VY - TradingView
Tvardi Therapeutics, Inc. (NASDAQ: TVRD) Share Price, TVRD Stock News, TVRD Share Price & Updates - Kalkine
Tvardi Therapeutics Company Profile & Introduction - Moomoo
ONDS: Ondas Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Tvardi Therapeutics Expands At-The-Market Equity Program - The Globe and Mail
Form 424B5 Tvardi Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Tvardi Therapeutics | 8-K: Current report - Moomoo
Tvardi Therapeutics (NASDAQ: TVRD) adds $9.69M capacity to ATM program - Stock Titan
Tvardi Therapeutics (TVRD) plans up to $9.7M Nasdaq at-the-market stock offering - Stock Titan
Tvardi Therapeutics | 424B5: Prospectus - Moomoo
Tvardi Therapeutics expands ATM program by $9.69M after prior $11.0M sales under JonesTrading - TradingView
symbol__ Stock Quote Price and Forecast - CNN
TVRD stock rallies 149% so far this week: Here's what you should know - MSN
Enterprise value to revenue forward of Tvardi Therapeutics Inc. – BX:TVRD - TradingView
Tvardi Therapeutics(TVRD) Stock Options Chain | Quotes & News - Moomoo
Tvardi Therapeutics (TVRD) Proxy filing Summary - Quartr
Tvardi Therapeutics (TVRD) Registration filing Summary - Quartr
Tvardi Therapeutics (TVRD) Company presentation Summary - Quartr
Tvardi Therapeutics (TVRD) Registration Filing Summary - Quartr
Tvardi Therapeutics (TVRD) Q4 2025 earnings summary - Quartr
Tvardi Therapeutics (TVRD) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Tvardi Therapeutics (TVRD) Slides 3.68% as Stock Tests Key Support LevelsCatalyst Driven Stocks - dars.gov.et
Tvardi Therapeutics Inc Stock (TVRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):